Research Reports | Market Assessment
December 2015

Hemophilia | Niche and Rare Pharmacor | G7 | 2015

Hemophilia is a monogenic bleeding disorder occurring primarily in males. In hemophilia A and hemophilia B, factor VIII or factor IX (respectively) is either absent or deficient in function. Several factor replacement serums are currently approved to treat hemophilia A and B, but a comparatively large unmet need remains for hemophilia A patients because of disappointing factor half-life extensions, compounded by the higher diagnosed prevalence of hemophilia A vs B. Launch of the new longer-acting factor concentrates and agents with novel mechanisms of action, for both type A and B, offer a chance to achieve improvements in clinical outcomes and address compliance issues. Using primary research conducted with expert U.S. and European hemophilia specialists, this report provides a comprehensive analysis of the competitive landscape and market opportunity for hemophilia. It includes a comprehensive analysis of patient populations, current therapies and medical practices, unmet needs, and emerging therapies.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports